Viking Therapeutics Inc. (VKTX) saw its shares plunge more than 40% following the release of disappointing data from a mid-stage (phase 2) clinical trial of its experimental weight-loss drug, VK2735. The trial results revealed a high patient dropout rate, which contributed to investor concerns and the steep decline in the stock price, which closed at $24.36. Despite the setback, some analysts remain optimistic about the drug’s potential. Laidlaw reiterated a Buy rating with a price target of $110, citing strong efficacy data and manageable safety profiles with dosing adjustments. Similarly, B. Riley maintained a Buy rating with an $85 target, suggesting the selloff was overdone and emphasizing VK2735’s role in maintenance therapy for obesity. Meanwhile, the broader GLP-1 drug market continues to evolve, with Eli Lilly’s obesity pill still considered a viable competitor to Novo Nordisk’s oral Wegovy despite some underwhelming data. Additionally, diabetes drug Ozempic, developed by Novo Nordisk, is expanding its indications to include kidney disease treatment, reinforcing its position in the crowded GLP-1 market. The popularity of GLP-1 drugs has also spurred a surge in supplement products claiming similar benefits. However, concerns about side effects, such as dental issues linked to Ozempic, have emerged. Upcoming medical conferences, including the EASD in September, are expected to provide further updates on obesity treatments, particularly from Eli Lilly.